Diuretic response in acute heart failure-an analysis from ASCEND-HF.
Jozine M ter Maaten, Allison M Dunning, Mattia A E Valente...
https://pubmed.ncbi.nlm.nih.gov/26299229/Actively Recruiting
Led by University of Siena · Updated on 2025-08-08
370
Participants Needed
4
Research Sites
N/A
Total Duration
Researchers are evaluating the best way to give intravenous loop diuretics to patients admitted with acutely decompensated heart failure ADHF. This study compares continuous infusion versus intermittent bolus infusion of furosemide, focusing on their effects on kidney function, signs of fluid overload, B-type natriuretic peptide BNP levels, and patient outcomes. The goal is to determine which administration method may better manage ADHF while considering potential risks and benefits. The study involves two groups of patients receiving either continuous intravenous infusion of furosemide or intermittent bolus intravenous infusions. These treatments are monitored during the hospital stay, typically lasting 7 to 12 days. Researchers will observe how these different infusion strategies affect heart failure symptoms, fluid removal, and kidney function over this period. Participants will be assessed regularly during hospitalization for changes in body weight, urine output, BNP levels, kidney function markers, and signs of fluid overload such as edema and lung congestion. The main outcomes include rates of cardiac death and rehospitalization for heart failure over 180 days, as well as secondary measures like length of hospital stay, use of additional medications, and improvements in congestion. The study aims to provide detailed data on how different furosemide infusion methods impact patient health and recovery.
CONDITIONS
Loop Diuretic Therapy in Acutely Decompensated Heart Failure
A
Alberto Palazzuoli, MD
G
Gaetano Ruocco, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Siena
Lead Sponsor
University of Roma La Sapienza
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 7 to 12 days
Participants receive either continuous or intermittent intravenous loop diuretic infusions to manage acutely decompensated heart failure during hospitalization.
Daily visits during hospital stay
Duration - Up to 180 days
Participants are monitored for cardiac death, rehospitalization, and diuretic efficiency outcomes after discharge.
Periodic follow-up visits up to 180 days
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Jozine M ter Maaten, Allison M Dunning, Mattia A E Valente...
https://pubmed.ncbi.nlm.nih.gov/26299229/Alberto Palazzuoli, Frank Loyd Dini, Nicola Riccardo Pugliese...
https://pubmed.ncbi.nlm.nih.gov/40314350/Alberto Palazzuoli, Gaetano Ruocco, Giorgio Vescovo...
https://pubmed.ncbi.nlm.nih.gov/28980452/Adriaan A Voors, Beth A Davison, John R Teerlink...
https://pubmed.ncbi.nlm.nih.gov/25287144/Alberto Palazzuoli, Marco Pellegrini, Gaetano Ruocco...
https://pubmed.ncbi.nlm.nih.gov/24974232/G Michael Felker, Kerry L Lee, David A Bull...
https://pubmed.ncbi.nlm.nih.gov/21366472/Anuradha Lala, Steven E McNulty, Robert J Mentz...
https://pubmed.ncbi.nlm.nih.gov/26041600/University of Siena
Lead Sponsor
University of Roma La Sapienza
Collaborating Sponsor